112334-43-7

Upstream product

• 112334-42-6 benzyl 4,5-bis(benzyloxy)picolinate 
• 59281-14-0 5-benzyloxy-4-hydroxy-2-hydroxymethylpyridine 
• 100-44-7 benzyl chloride 
• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 
• 59281-14-0 5-benzyloxy-2-hydroxymethyl-1H-pyridin-4-one 

Relevant academic research and scientific papers

Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections

Conjugating a siderophore to an antibiotic is a promising strategy to overcome the permeability-mediated resistance of Gram-negative pathogens. On the basis of the structure of BAL30072, novel pyridone-conjugated monosulfactams incorporating diverse substituents into the methylene linker between the 1,3-dihydroxypyridin-4(1H)-one and the aminothiazole oxime were designed and synthesized. Structure-activity relationship studies revealed that a variety of substituents were tolerated, with isopropyl (compound 12c) and methylthiomethyl (compound 16a) showing the best efficacy against multidrug-resistant (MDR) Gram-negative pathogens. In addition, compound 12c exhibits a good free fraction rate in an in vitro human plasma protein binding test, along with a low clearance and favorable plasma exposure in vivo. In a murine systemic infection model with MDR Klebsiella pneumoniae, compound 12c shows an ED50 of 10.20 mg/kg. Taken together, the results indicate that compound 12c is a promising drug candidate for the treatment of serious infections caused by MDR Gram-negative pathogens.

Pyridone-conjugated monobactam antibiotics with gram-negative activity

Herein we describe the structure-aided design and synthesis of a series of pyridone-conjugated monobactam analogues with in vitro antibacterial activity against clinically relevant Gram-negative species including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Rat pharmacokinetic studies with compound 17 demonstrate low clearance and low plasma protein binding. In addition, evidence is provided for a number of analogues suggesting that the siderophore receptors PiuA and PirA play a role in drug uptake in P. aeruginosa strain PAO1.

MONOBACTAMS

The present invention is directed to a new class of monobactam derivatives and their use for treating bacterial infections.

6- or 7-beta-[2-[4-(substituted)-2,3-dioxopiperazin-1-yl) carbonylamino]-(substituted)acetamido]-penicillin and cephalosporin derivatives

Antibacterial agents have the formula (I) or are pharmaceutically acceptable salts or invivohydrolysable esters thereof: in which Y1 is oxygen, sulphur or -CH2 and Z represents hydrogen, halogen, C1-4alkoxy, -CH2-Q or -CH=CH-Q where Q represents hydrogen, halogen, hydroxy, mercapto, cyano, carboxy, carboxylic ester, C1-4alkyloxy, acyloxy, aryl, a heterocyclyl group bonded via carbon, a heterocyclylthio group or a nitrogen containing heterocyclic group bonded via nitrogen;, R5 represents phenyl, substituted phenyl, cyclohexenyl, cyclohexadienyl or an optionally substituted 5 or 6-membered heterocyclic ring containing up to three hetero atoms selected from oxygen, sulphur or nitrogen, R6 is hydrogen, hydroxymethyl, formamido, or methoxy, R7 and R8 are the same or different and represent hydrogen, C1-6alkyl, substituted C1-6alkyl, halogen, amino, phenyl, substituted phenyl, hydroxy or C1-6alkoxy or R7 and R8 form the residue of an optionally substituted 5 or 6- membered carbocyclic ring or a 5 or 6-membered heterocyclic ring containing up to three hetero atoms selected from oxygen, sulphur or nitrogen, R9 is wherein R10 and R11 are the same or different and each represents hydroxy, or protected hydroxy and XR9 is -(CH2)nR9, -NHCOR9, -N=CHR9, -NHCH2R9, or -COR9, where n is from 0 to 2; with the proviso that XR9 does not represent -N=CHR9 when R6 represents hydrogen. The use of the compounds is described together with intermediates for their preparation.

2-oxo-1-[[(substituted sulfonyl)amino]carbonyl]azetidines

Antibacterial activity is exhibited by 2-azetidinones having a 3-acylamino substituent and having an activating group in the 1-position of the formula STR1